South Korea Prediabetes Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), and DPP-4 Inhibitors), By Age Group (Children, Adult, and Elderly), and South Korea Prediabetes Market Insights, Industry Trend, Forecasts to 2035

South Korea Prediabetes Market Insights Forecasts to 2035

• The South Korea Prediabetes Market Size Was Estimated at USD 5.56 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 12.28% from 2025 to 2035
• The South Korea Prediabetes Market Size is Expected to Reach USD 19.87 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The South Korea Prediabetes Market Size is anticipated to Reach USD 19.87 Million by 2035, Growing at a CAGR of 12.28% from 2025 to 2035. The prediabetes business is the rising prevalence of diseases that result in insulin resistance and poor glucose metabolism and are caused by mutations in particular genes.

Market Overview

The business environment that includes goods and services for identifying, treating, and maybe halting the development of prediabetes into type 2 diabetes is referred to as the prediabetes market. This includes digital health solutions like wearable technology and smartphone apps, therapeutic alternatives including lifestyle management plans and prescription drugs, and diagnostic tools like blood glucose monitors. By identifying those at risk before they acquire type 2 diabetes, prediabetes screens enable prompt therapy. To control prediabetes and maybe prevent or postpone the onset of type 2 diabetes, medications such as metformin and more recent ones like SGLT-2 inhibitors and GLP-1 receptor agonists are also employed. The treatments, since these newer pharmacological classes are demonstrating promise in the management of prediabetes and in lowering the risk of progression to type 2 diabetes. States and UTs receive funding to give free necessary medications, such as insulin, to individuals in need. Supports studies on metabolic syndrome and diabetes that concentrate on figuring out new therapeutic targets, treating morbidities, and comprehending molecular pathways.

Report Coverage

This research report categorizes the market for South Korea prediabetes market based on various segments and regions forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea prediabetes market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea prediabetes market.

Driving Factors

The rising reginal prevalence of obesity, sedentary lifestyles, and unhealthy dietary habits, which increase the risk of developing type 2 diabetes. Early screening initiatives and growing public awareness about the health risks of prediabetes are promoting timely diagnosis and intervention. Advancements in diagnostic technologies and effective pharmacological treatments further support market growth.

Restraining Factors

The low diagnosis rates, as many individuals remain unaware of their condition. Limited awareness, especially in early stages, reduces timely medical intervention. High dependency on lifestyle modifications over pharmacological treatments also affects drug market growth.

Market Segmentation

The South Korea prediabetes market share is classified into drug class and age group. 

• The diguanide segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea prediabetes market is segmented by drug class into diguanide, thiazolidinediones, glucagon-like peptide-1 agonists (GLP-1), and DPP-4 inhibitors. Among these, the diguanide segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. Its proven efficacy in improving insulin sensitivity and lowering blood glucose levels. Its widespread clinical use, affordability, and strong safety profile drive demand, supported by increasing prediabetes prevalence and emphasis on early intervention to prevent type 2 diabetes.

• The children segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea prediabetes market is segmented by age group into children, adult, and elderly. Among these, the children segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The rising childhood obesity and sedentary lifestyles. Increased awareness of early metabolic disorders and proactive screening in pediatric populations are driving demand for preventive treatments, supporting substantial growth in managing prediabetes among children.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea prediabetes market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List Of Key Companies

• Pulmuone
• Korea Ginseng Corp (KGC)
• CJ Wellcare
• Yuhan Corporation
• Daewoong Pharmaceutical
• Hanmi Pharmaceutical
• Chong Kun Dang Pharmaceutical
• GC Biopharma ( Green Cross Corp)
• Samsung Biologics
• GeneMatrix
• Macrogen ( genomics service provider)
• Pulmuone Green Juice (a division of Pulmuone focused on blood-sugar products)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea prediabetes market based on the below-mentioned segments:

 South Korea Prediabetes Market, By Drug Class

• Diguanide
• Thiazolidinediones
• Glucagon-like Peptide-1 Agonists (GLP-1)
• DPP-4 Inhibitors

South Korea Prediabetes Market, By Age Group

• Children
• Adult
• Elderly